Current and emerging therapies for bone metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

A paucity of therapeutic options is available to treat men with metastatic castration-resistant prostate cancer (mCRPC). However, recent developments in our understanding of the disease have resulted in several new therapies that show promise in improving overall survival rates in this patient population.

Methods

Agents approved for use in the United States and those undergoing clinical trials for the treatment of mCRPC are reviewed. Recent contributions to the understanding of prostate biology and bone metastasis are discussed as well as how the underlying mechanisms may represent opportunities for therapeutic intervention. New challenges to delivering effective mCRPC treatment will also be examined.

Results

New and emerging treatments that target androgen

SUBMITTER: Frieling JS 

PROVIDER: S-EPMC4673894 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature